Related references
Note: Only part of the references are listed.The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma
Richard Cathomas et al.
EUROPEAN UROLOGY (2022)
European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update
Morgan Roupret et al.
EUROPEAN UROLOGY (2021)
Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE)
Simon J. Crabb et al.
CLINICAL CANCER RESEARCH (2021)
Enhanced Detection of Genitourinary Cancers Using Fragmentation and Copy Number Profiles Obtained from Urinary Cell-Free DNA
Yang Han et al.
CLINICAL CHEMISTRY (2021)
Molecular classification and diagnostics of upper urinary tract urothelial carcinoma
Yoichi Fujii et al.
CANCER CELL (2021)
A Novel CpG Methylation Risk Indicator for Predicting Prognosis in Bladder Cancer
Yufeng Guo et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
Comprehensive integrative profiling of upper tract urothelial carcinomas
Xiaoping Su et al.
GENOME BIOLOGY (2021)
Noninvasive Detection and Localization of Genitourinary Cancers Using Urinary Sediment DNA Methylomes and Copy Number Profiles
Zhengzheng Xu et al.
EUROPEAN UROLOGY (2020)
Urothelial Carcinoma Detection Based on Copy Number Profiles of Urinary Cell-Free DNA by Shallow Whole-Genome Sequencing
Guangzhe Ge et al.
CLINICAL CHEMISTRY (2020)
Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial
Alison Birtle et al.
LANCET (2020)
Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling
Brian D. Robinson et al.
NATURE COMMUNICATIONS (2019)
Integrative Epigenetic Analysis Reveals Therapeutic Targets to the DNA Methyltransferase Inhibitor Guadecitabine (SGI-110) in Hepatocellular Carcinoma
Minmin Liu et al.
HEPATOLOGY (2018)
Integrative analysis of the epigenetic basis of muscle-invasive urothelial carcinoma
Thomas Sanford et al.
CLINICAL EPIGENETICS (2018)
TIP: A Web Server for Resolving Tumor Immunophenotype Profiling
Liwen Xu et al.
CANCER RESEARCH (2018)
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan et al.
NATURE (2018)
Epigenetic Alterations in Bladder Cancer
Sima P. Porten
CURRENT UROLOGY REPORTS (2018)
Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma
Tyler J. Moss et al.
EUROPEAN UROLOGY (2017)
Identification of methylation haplotype blocks aids in deconvolution of heterogeneous tissue samples and tumor tissue-of-origin mapping from plasma DNA
Shicheng Guo et al.
NATURE GENETICS (2017)
Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression
Etienne Becht et al.
GENOME BIOLOGY (2016)
DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts
David Roulois et al.
CELL (2015)
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses
Katherine B. Chiappinelli et al.
CELL (2015)
Prognostic and predictive value of epigenetic biomarkers and clinical factors in upper tract urothelial carcinoma
Gengyan Xiong et al.
EPIGENOMICS (2015)
5-Azacytidine enhances efficacy of multiple chemotherapy drugs in AML and lung cancer with modulation of CpG methylation
Mathias Fueller et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2015)
Molecular Analysis of Upper Tract and Bladder Urothelial Carcinoma: Results from a Microarray Comparison
Thomas Sanford et al.
PLOS ONE (2015)
Gene Body Methylation Can Alter Gene Expression and Is a Therapeutic Target in Cancer
Xiaojing Yang et al.
CANCER CELL (2014)
5-Azacytidine treatment sensitizes tumor cells to T-cell mediated cytotoxicity and modulates NK cells in patients with myeloid malignancies
A. O. Gang et al.
BLOOD CANCER JOURNAL (2014)
Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers
Huili Li et al.
ONCOTARGET (2014)
Epidemiology and Risk Factors of Urothelial Bladder Cancer
Maximilian Burger et al.
EUROPEAN UROLOGY (2013)
Inferring tumour purity and stromal and immune cell admixture from expression data
Kosuke Yoshihara et al.
NATURE COMMUNICATIONS (2013)
Transient Low Doses of DNA-Demethylating Agents Exert Durable Antitumor Effects on Hematological and Epithelial Tumor Cells
Hsing-Chen Tsai et al.
CANCER CELL (2012)
Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guerin
Sultan S. Alkhateeb et al.
UROLOGY ANNALS (2011)
Unique DNA Methylation Patterns Distinguish Noninvasive and Invasive Urothelial Cancers and Establish an Epigenetic Field Defect in Premalignant Tissue
Erika M. Wolff et al.
CANCER RESEARCH (2010)
Molecular Grade (FGFR3/MIB-1) and EORTC Risk Scores Are Predictive in Primary Non-Muscle-Invasive Bladder Cancer
Bas W. G. van Rhijn et al.
EUROPEAN UROLOGY (2010)
Demethylating agent 5-aza-2 '-deoxycytidine enhances susceptibility of bladder transitional cell carcinoma to cisplatin
Donghao Shang et al.
UROLOGY (2008)
Delivery of 5-aza-2′-deoxycytidine to cells using oligodeoxynucleotides
Christine B. Yoo et al.
CANCER RESEARCH (2007)
Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma
JWF Catto et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Gemcitabine and cisplatin versus methotrexate vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large randomized, multinational, multicenter, phase III study
H von der Maase et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)